Polar Capital Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Polar Capital Holdings’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-87,500	Closed	-$39M	–	300
2025 Q2	$39M	Sell	87,500 -37,500	-30%	-$17.3M	0.2%	101
2025 Q1	$60.6M	Sell	125,000 -50,000	-29%	-$23.3M	0.37%	82
2024 Q4	$70.5M	Hold	175,000	–	–	0.39%	69
2024 Q3	$81.4M	Hold	175,000	–	–	0.39%	58
2024 Q2	$82M	Hold	175,000	–	–	0.48%	58
2024 Q1	$73.2M	Hold	175,000	–	–	0.38%	68
2023 Q4	$71.2M	Sell	175,000 -200,000	-53%	-$73.9M	0.44%	65
2023 Q3	$130M	Hold	375,000	–	–	0.97%	20
2023 Q2	$132M	Hold	375,000	–	–	0.67%	26
2023 Q1	$118M	Buy	375,000 +85,000	+29%	+$25.5M	0.77%	29
2022 Q4	$83.7M	Sell	290,000 -280	-0.1%	-$85.3K	0.67%	45
2022 Q3	$84K	Sell	290,280 -10,000	-3%	-$2.88M	0.54%	45
2022 Q2	$84.6K	Hold	300,280	–	–	0.5%	46
2022 Q1	$78.4K	Sell	300,280 -74,720	-20%	-$17.7M	0.35%	66
2021 Q4	$82.3K	Buy	375,000 +75,000	+25%	+$14.6M	0.31%	73
2021 Q3	$54.4K	Hold	300,000	–	–	0.22%	103
2021 Q2	$60.5K	Sell	300,000 -25,000	-8%	-$5.23M	0.26%	89
2021 Q1	$69.8M	Buy	325,000 +50,000	+18%	+$11M	0.43%	70
2020 Q4	$65M	Buy	+275,000	New	+$63.1M	0.39%	74

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Polar Capital Holdings's VRTX Position: Q3 2025 in Review

Polar Capital Holdings sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 87,500 shares — an estimated $39M sold.

Polar Capital Holdings first reported a position in VRTX in Q4 2020 and held it in 19 quarters. The position peaked at $132M in Q2 2023. 1,520 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

Polar Capital Holdings reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Polar Capital Holdings sold 87,500 Vertex Pharmaceuticals shares in Q3 2025, an estimated $39M.
Polar Capital Holdings first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 19 quarters.
Polar Capital Holdings's Vertex Pharmaceuticals position peaked at $132M in Q2 2023.
1,520 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Polar Capital Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.